90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

Felipe Samaniego*, Zuzana Berkova, Jorge E. Romaguera, Nathan Fowler, Michelle A. Fanale, Barbara Pro, Jatin J. Shah, Peter Mclaughlin, Lalit Sehgal, Vijairam Selvaraj, Frank K. Braun, Rohit Mathur, Lei Feng, Sattva S. Neelapu, Larry W. Kwak

*Corresponding author for this work

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

90Y-ibritumomab-tiuxetan (90YIT) was used as a first-line therapy for patients with early-stage follicular lymphoma (FL) or marginal zone B-cell lymphoma (MZL). Thirty-one patients were treated, with an overall 3-month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow-up of 56 months, ten patients (32%) had disease relapse or progression. The progression-free rates at 3 and 5 years were lower in males, patients with FL, stage II diseaseand non-bulky disease, although they did not reach statistical significance. Grade 3-4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. 90YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early-stage low-grade B-cell lymphomas. Bulky disease did not adversely affect tumour response.

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalBritish Journal of Haematology
Volume167
Issue number2
DOIs
StatePublished - Oct 1 2014

Keywords

  • Follicular
  • Marginal zone
  • Myelosuppression
  • Radiation
  • Zevalin

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of '<sup>90</sup>Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease'. Together they form a unique fingerprint.

Cite this